Phase 1/2 Adaptive Design Trial to Evaluate the Immunogenicity and Safety of Panblok (H7 rHA) at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With Unadjuvanted H7 rHA in Healthy Adults Aged 18 and Older

Trial Profile

Phase 1/2 Adaptive Design Trial to Evaluate the Immunogenicity and Safety of Panblok (H7 rHA) at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With Unadjuvanted H7 rHA in Healthy Adults Aged 18 and Older

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs PanBlok (Primary) ; Adjuvants
  • Indications Influenza A virus infections
  • Focus Pharmacodynamics
  • Sponsors Protein Sciences Corporation
  • Most Recent Events

    • 25 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 29 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.
    • 26 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top